ABOUT REBLOZYL:
PATIENT IDENTIFICATION
SEE DOSING RECOMMENDATIONS
Explore 2 common hypothetical REBLOZYL dosing cases
Robert started treatment with REBLOZYL but has not achieved response after his first 2 doses
Age: 70
Baseline labs:
EPO level: 180 U/L
Hgb: 8.5 g/dL
Treatment goals:
Hgb increase by at least 1.5 g/dL and transfusion independence
Treatment history:
No prior treatment with ESAs. Started REBLOZYL as a first-line treatment and has received 2 doses of REBLOZYL 1 mg/kg Q3W. He was transfusion dependent for the last 2 months
Monitor response
Before the third dose:
- Hgb: 9.3 g/dL
- Transfusion needs: none
- Tolerability: no Grade 3/4 adverse reactions observed
Increase to a therapeutic dose
- Increased to a dose of 1.33 mg/kg to achieve sufficient response
- Team will continue monitoring his Hgb, transfusion needs, and tolerability
If a patient like Robert clinically requires transfusions but isn't able to receive one, REBLOZYL could be considered for this patient.
Hypothetical case. Model, not actual patient.
Michael’s treatment was reduced due to rapid hemoglobin rise
Age: 75
Baseline labs:
EPO level: 60 U/L
Hgb: 9.5 g/dL
Treatment goals:
Hgb increase by at least 1.5 g/dL and transfusion independence
Treatment history:
Has not yet received an ESA or REBLOZYL. Started REBLOZYL at 1 mg/kg. He was transfusion dependent within the last 2 months
Monitor response
Before Michael’s second dose:
- Hgb: 11.8 g/dL (increased 2.3 g/dL from baseline in a 3-week period)
- Transfusion needs: none
- Tolerability: no Grade 3/4 adverse reactions observed
Reduce dose for rapid Hgb increase
- His dose was reduced to 0.8 mg/kg
- Team will continue monitoring his Hgb, transfusion needs, and tolerability
If a patient like Michael clinically requires transfusions but isn't able to receive one, REBLOZYL could be considered for this patient.
Hypothetical case. Model, not actual patient.
ESA=erythropoiesis-stimulating agent; EPO=erythropoietin; Hgb=hemoglobin; Q3W=every 3 weeks.
